Targeting of Evolutionarily Acquired Cancer Cell Phenotype by Exploiting pHi-Metabolic Vulnerabilities.

3D co-culture cancer cells subpopulations darwinian evolution diclofenac evolutionary therapy koningic acid spheroid tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Dec 2020
Historique:
received: 14 11 2020
revised: 14 12 2020
accepted: 23 12 2020
entrez: 31 12 2020
pubmed: 1 1 2021
medline: 1 1 2021
Statut: epublish

Résumé

Evolutionary dynamics can be used to control cancers when a cure is not clinically considered to be achievable. Understanding Darwinian intratumoral interactions of microenvironmental selection forces can be used to steer tumor progression towards a less invasive trajectory. Here, we approach intratumoral heterogeneity and evolution as a dynamic interaction among subpopulations through the application of small, but selective biological forces such as intracellular pH (pHi) and/or extracellular pH (pHe) vulnerabilities. Increased glycolysis is a prominent phenotype of cancer cells under hypoxia or normoxia (Warburg effect). Glycolysis leads to an important aspect of cancer metabolism: reduced pHe and higher pHi. We recently showed that decreasing pHi and targeting pHi sensitive enzymes can reverse the Warburg effect (WE) phenotype and inhibit tumor progression. Herein, we used diclofenac (DIC) repurposed to control MCT activity, and Koningic acid (KA) that is a GAPDH partial inhibitor, and observed that we can control the subpopulation of cancer cells with WE phenotype within a tumor in favor of a less aggressive phenotype without a WE to control progression and metastasis. In a 3D spheroid co-cultures, we showed that our strategy can control the growth of more aggressive MDA-MB-231 cells, while sparing the less aggressive MCF7 cells. In an animal model, we show that our approach can reduce tumor growth and metastasis. We thus propose that evolutionary dynamics can be used to control tumor cells' clonal or sub-clonal populations in favor of slower growth and less damage to patients. We propose that this can result in cancer control for tumors where cure is not an option.

Identifiants

pubmed: 33379345
pii: cancers13010064
doi: 10.3390/cancers13010064
pmc: PMC7795337
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : R01CA077571
Pays : United States
Organisme : NIH HHS
ID : 1U54CA193489
Pays : United States

Références

Science. 1928 Nov 9;68(1767):437-43
pubmed: 17782077
Cancer Res. 2017 Oct 1;77(19):5409-5418
pubmed: 28754669
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
Cell Cycle. 2017 Oct 2;16(19):1739-1743
pubmed: 27635863
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Cancer Res. 2017 May 1;77(9):2242-2254
pubmed: 28249898
PLoS Comput Biol. 2015 Sep 11;11(9):e1004493
pubmed: 26360300
PLoS One. 2009 Jul 03;4(7):e6146
pubmed: 19582160
Nat Commun. 2017 Nov 28;8(1):1816
pubmed: 29180633
Nat Commun. 2018 Jul 31;9(1):2997
pubmed: 30065243
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):162-166
pubmed: 28341421
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Curr Med Res Opin. 2010 Jul;26(7):1715-31
pubmed: 20470236
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
J Biol Chem. 2014 Sep 12;289(37):25418-30
pubmed: 25059669
Oncotarget. 2015 Jun 20;6(17):14777-95
pubmed: 26087310
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Nat Commun. 2015 Dec 10;6:8752
pubmed: 26658462
Cancer Res. 2020 Apr 1;80(7):1578-1589
pubmed: 31948939
Nat Commun. 2020 Mar 24;11(1):1533
pubmed: 32210228
Mol Cancer. 2016 Jun 06;15(1):45
pubmed: 27266704
Cell Rep. 2019 Oct 1;29(1):135-150.e9
pubmed: 31577944
J Antibiot (Tokyo). 1985 Jul;38(7):920-5
pubmed: 4030504
Cancer Res. 1997 Aug 1;57(15):3071-8
pubmed: 9242427
Nat Rev Cancer. 2008 Jan;8(1):56-61
pubmed: 18059462
Sci Transl Med. 2016 Feb 24;8(327):327ra24
pubmed: 26912903
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Neoplasia. 2017 Feb;19(2):121-134
pubmed: 28092823
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Steroids. 1975 Dec;26(6):785-95
pubmed: 175527
J Biol Chem. 2020 Jan 3;295(1):111-124
pubmed: 31748414
Cancer Res. 2014 Feb 1;74(3):908-20
pubmed: 24285728
Cell Metab. 2017 Oct 3;26(4):648-659.e8
pubmed: 28918937
Biochim Biophys Acta. 2016 Oct;1863(10):2465-80
pubmed: 26944480

Auteurs

Bryce Ordway (B)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Michal Tomaszewski (M)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Samantha Byrne (S)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Dominique Abrahams (D)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Pawel Swietach (P)

Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford OX1 3PT, UK.

Robert J Gillies (RJ)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Mehdi Damaghi (M)

Department of Cancer Physiology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Classifications MeSH